ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Neutrophil-Lymphocyte Ratio May be Used as a Biomarker for Predicting Progression of Barrett's Esophagus to Esophageal Adenocarcinoma: A Retrospective Cohort Study.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic inflammatory biomarkers in gastroesophageal reflux disease: current evidence and future perspectives.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study aims to investigate the correlation between the neutrophil-lymphocyte ratio (NLR) and advancing stages of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC). Methods and Results: A retrospective cohort of patients diagnosed with BE and EAC were analyzed. Cases were categorized into four groups according to their histological diagnosis: non-dysplastic BE (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC. The NLR was calculated from a complete blood cell count within 6 months prior to diagnosis. A total of 140 patients were analyzed with a mean age of 67. The majority of patients were male (78.6%) and Caucasian (96.4%). Of the total, 32 (22.9%) patients had NDBE, 20 (14.3%) had LGD, 20 (14.3%) had HGD, and 68 (48.6%) had EAC. There was a statistically significant difference in NLR scores across the histological diagnoses. The mean NLR rank scores were 48.22 for NDBE, 44.75 for LGD, 60.35 for HGD, and 91.54 for EAC. Post hoc tests confirmed significant differences in NLR between NDBE and EAC, as well as LGD and EAC. Conclusions: The study supports the potential use of NLR as a biomarker for predicting histologic progression in BE to EAC. The NLR could serve as a useful adjunct to current surveillance strategies to help guide clinical decision-making. Further research is necessary to validate these findings and determine the clinical utility of NLR as a predictor for dysplasia and neoplasia in BE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.